{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:27:52Z","timestamp":1761128872098},"reference-count":58,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.jbspin.2010.09.002","type":"journal-article","created":{"date-parts":[[2010,10,19]],"date-time":"2010-10-19T13:47:19Z","timestamp":1287496039000},"page":"511-516","source":"Crossref","is-referenced-by-count":27,"title":["Current treatments for juvenile idiopathic arthritis"],"prefix":"10.1016","volume":"77","author":[{"given":"Pierre","family":"Quartier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2010.09.002_bib0005","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11926-010-0087-0","article-title":"The genetics of juvenile idiopathic arthritis: what is new in 2010?","volume":"12","author":"Angeles-Han","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0015","first-page":"927","article-title":"Juvenile idiopathic arthritides evaluated prospectively in a single center according to the Durban criteria","volume":"28","author":"Hofer","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0020","article-title":"Epidemiologie","author":"Minden K","year":"2007"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0025","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/art.20945","article-title":"Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease","volume":"52","author":"Ravelli","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0030","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.ophtha.2009.12.003","article-title":"Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids","volume":"11","author":"Thorne","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0035","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jbspin.2008.10.015","article-title":"Ocular threat in juvenile idiopathic arthritis","volume":"76","author":"Marvillet","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0040","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0045","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S1297-319X(02)00432-3","article-title":"Validation of the French version of the Childhood Health Assessment Questionnaire (CHAQ) in juvenile idiopathic arthritis","volume":"69","author":"Pouchot","year":"2002","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0050","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00247-010-1612-z","article-title":"Synovial and inflammatory diseases in childhood: role of new imaging modalities in the assessment of patients with juvenile idiopathic arthritis","volume":"40","author":"Damasio","year":"2010","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0055","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/art.23916","article-title":"Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis","volume":"59","author":"Magni-Manzoni","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0060","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0065","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.arcped.2010.04.002","article-title":"Recommandations pour la prise en charge des formes oligoarticulaire et polyarticulaires (en dehors de la polyarthrite rhumato\u00efde) d\u2019arthrite juv\u00e9nile idiopathique","volume":"17","author":"Bader-Meunier","year":"2010","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0070","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F","article-title":"Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis","volume":"43","author":"Woo","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0075","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.24087","article-title":"Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis","volume":"61","author":"Albers","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0080","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3899\/jrheum.090826","article-title":"Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens","volume":"37","author":"Becker","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0085","first-page":"1047","article-title":"Methotrexate bioavailability after oral and subcutaneous administration in children with juvenile idiopathic arthritis","volume":"27","author":"Tukov\u00e1","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0090","doi-asserted-by":"crossref","unstructured":"Tukov\u00e1 J, Chl\u00e1dek J, Hroch M, et al. 677TT Genotype is associated with elevated risk of methotrexate (mtx) toxicity in juvenile idiopathic arthritis: treatment outcome, erythrocyte concentrations of MTX and folates, and MTHFR polymorphisms. J Rheumatol 2010;37:2180\u20136.","DOI":"10.3899\/jrheum.091427"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0095","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/ard.2007.073445","article-title":"The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis","volume":"67","author":"Bartoli","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"1266\u201373","key":"10.1016\/j.jbspin.2010.09.002_bib0100","article-title":"Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial","volume":"303","author":"Foell","year":"2010","journal-title":"JAMA 2010"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0105","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/112067210701700509","article-title":"Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication","volume":"17","author":"Heiligenhaus","year":"2007","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0110","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa041810","article-title":"Leflunomide or methotrexate for juvenile rheumatoid arthritis","volume":"352","author":"Silverman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0115","doi-asserted-by":"crossref","unstructured":"Bader-Meunier B, Wouters C, Job-Deslandre C, et al. Recommandations pour la prise en charge de la forme syst\u00e9mique l\u2019arthrite juv\u00e9nile idiopathique (maladie de Still). Arch Pediatr 2010;17:1090\u20134.","DOI":"10.1016\/j.arcped.2010.04.001"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0120","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jpeds.2004.08.020","article-title":"Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study","volume":"145","author":"Lehman","year":"2004","journal-title":"J Pediatr"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0125","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1136\/ard.2003.017798","article-title":"Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity","volume":"63","author":"De Kleer","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0130","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0135","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.10885","article-title":"Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type","volume":"48","author":"Quartier","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0140","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/ard.2003.014886","article-title":"The German etanercept registry for treatment of juvenile idiopathic arthritis","volume":"63","author":"Horneff","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0145","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0150","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0155","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0160","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0165","doi-asserted-by":"crossref","unstructured":"Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010;62:2183\u20134.","DOI":"10.1002\/art.27511"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0170","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00296-008-0563-2","article-title":"Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years","volume":"10","author":"Tzaribachev","year":"2008","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0175","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/ard.2007.087593","article-title":"Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry","volume":"68","author":"Horneff","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0180","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.2007.087411","article-title":"Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register","volume":"68","author":"Prince","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0185","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","article-title":"Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis","volume":"58","author":"Lovell","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0190","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/art.24777","article-title":"Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis","volume":"60","author":"Giannini","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0195","doi-asserted-by":"crossref","unstructured":"Dallocchio A, Canioni D, Ruemmele F, et al. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology (Oxford) 2010;49:1694\u20138.","DOI":"10.1093\/rheumatology\/keq136"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0200","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/rheumatology\/kem356","article-title":"Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis","volume":"47","author":"Tynj\u00e4l\u00e4","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0205","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.2009.100354","article-title":"Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension","volume":"69","author":"Ruperto","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0210","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0215","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France","volume":"67","author":"Lequerr\u00e9","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0220","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","article-title":"The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0225","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/RHU.0b013e3181a4f459","article-title":"Anakinra for systemic juvenile arthritis: the Rocky Mountain experience","volume":"15","author":"Zeft","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0230","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10067-008-0995-9","article-title":"Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study","volume":"28","author":"Ilowite","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0235","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1056\/NEJMe0811014","article-title":"Interleukin-1beta and the autoinflammatory diseases","volume":"360","author":"Dinarello","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0240","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/BOR.0b013e32832f1445","article-title":"Targeting interleukin-6 in pediatric rheumatic diseases","volume":"21","author":"De Benedetti","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0245","unstructured":"De Benedetti F, et al. EULAR 2010, Roma. OP0273. Efficacy and safety of tocilizumab in patients with systemic juvenile idiopathic arthritis (SJIA); 12-week data from the phase 3 Tender trial."},{"issue":"Suppl. II","key":"10.1016\/j.jbspin.2010.09.002_bib0250","first-page":"550","article-title":"Efficacy and safety in 48-week treatment of tocilizumab in children with polyarticular course juvenile idiopathic arthritis with polyarticular or oligoarticular onset","volume":"66","author":"Imagawa","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0255","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/acr.20115","article-title":"Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis","volume":"62","author":"Zulian","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0260","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/rheumatology\/keq123","article-title":"Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis","volume":"49","author":"Billiau","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0265","doi-asserted-by":"crossref","unstructured":"Giannini EH, Ilowite NT, Lovell DJ, et al. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2010 Jul 28 [Epub ahead of print].","DOI":"10.1002\/art.27682"},{"issue":"Suppl. 1","key":"10.1016\/j.jbspin.2010.09.002_bib0270","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000229765","article-title":"Effects of growth hormone treatment on growth in children with juvenile idiopathic arthritis","volume":"72","author":"Simon","year":"2009","journal-title":"Horm Res"},{"issue":"Suppl. 1","key":"10.1016\/j.jbspin.2010.09.002_bib0275","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000229767","article-title":"Safety of growth hormone treatment in children with juvenile idiopathic arthritis","volume":"72","author":"Simon","year":"2009","journal-title":"Horm Res"},{"issue":"Suppl. 1","key":"10.1016\/j.jbspin.2010.09.002_bib0280","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000229766","article-title":"Effects of growth hormone treatment in juvenile idiopathic arthritis: bone and body composition","volume":"72","author":"Bechtold","year":"2009","journal-title":"Horm Res"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0285","doi-asserted-by":"crossref","unstructured":"Ruperto N, Lovell DJ, Li T, et al. Abatacept improves health-related quality of life, pain, sleep quality and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2010 Jul 1 [Epub ahead of print].","DOI":"10.1002\/acr.20283"},{"key":"10.1016\/j.jbspin.2010.09.002_bib0290","doi-asserted-by":"crossref","unstructured":"Stinson JN, McGrath PJ, Hodnett ED, et al. An Internet-based self-management program with telephone support for adolescents with arthritis: a pilot randomized controlled trial. J Rheumatol 2010;37:1944\u201352.","DOI":"10.3899\/jrheum.091327"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X10002332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X10002332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T16:16:02Z","timestamp":1559751362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X10002332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S1297319X10002332"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2010.09.002","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}